Given the increased attention of clinicians, researchers, and the pharmaceutical industry to the management and treatment of dementia not only in the elderly but also in increasingly younger populations, the demands for effective evidence-based pharmaceutical control of dementia and quantitative assessment of outcomes have increased.

List of Contributors, Preface, 1. Introduction: Expectations of Treatment with the Cholinesterase Inhibition Strategy, 2. The History of Therapeutic Trials in Dementia, 3. Treatment Hypotheses, 4. Clinical Trial Designs and Endpoint Selection, 5. The Use of Qualitative Research, 6. Inclusion and Exclusion Criteria, 7. Global Assessment Measures, 8. Cognitive Outcomes, 9. Functional Outcomes, 10. Behavioural Outcomes, 11. Quality of Life Outcomes, 12. Caregiver Burden Outcomes, 13. Structural Neuroimaging Outcomes, 14. Guidelines for Randomised Clinical Studies in Parkinson's Disease with Dementia and Dementia with Lewy Bodies, 15. Clinical Trials for Vascular Cognitive Impairment, 16. Clinical Trials for Primary Prevention in Dementia, 17. Clinical Trials for Memantine, 18. Clinical Trials for Psychotropic Agents in Alzheimer's Disease, 19. Clinical Trials for Psychosocial Interventions Aimed at Caregivers of People with Dementia, 20. Pharmacoeconomic Outcomes, 21. Executive Dysfunction in Dementia, 22. Ethical Considerations in the Conduct of Clinical Trials for Alzheimer's Disease, 23. Designs for Trials when there is a Standard Therapy: Superiority, Equivalence, Non-inferiority, 24. Conclusion: Lessons from Clinical Trials in Dementia, Index

Kenneth Rockwood MD MPA FRCPC is Professor, Division of Geriatric Medicine, Department of Medicine and Kathryn Allen Weldon Professor of Alzheimer Research, Dalhousie University, Halifax NS, Canada. Serge Gauthier MD FRCPC is Professor and Director of the Alzheimer's Disease Research Unit, The McGill Centre for Studies in Aging (Le Centre McGill D'Études sur le Vieillissement), Douglas Hospital, Montréal PQ, Canada.